Proteomics International signs with PrismHealthDx for US launch of PromarkerD predictive test for diabetic kidney disease
04 June 2018 - 12:00PM
JCN Newswire (English)
PERTH, W. AUSTRALIA, June 4, 2018 - (ACN Newswire) - Medical
technology company Proteomics International Laboratories Ltd
(Proteomics International; ASX: PIQ) has signed the first licence
agreement for its world-leading PromarkerD predictive test for
diabetic kidney disease in the United States, creating a
partnership with US-based precision medicine and diagnostic
services laboratory PrismHealthDx, Inc. (PHDx ).
Proteomics International has granted PHDx, head-quartered in
Austin, Texas, a licence for the clinical market in the USA to make
PromarkerD available to the more than 30 million Americans living
with diabetes. Commercial details for the licensing agreement
remain confidential.
The USA has one of the highest rates of diabetes in the world and
is by far the biggest spending country on diabetes-related
healthcare. Kidney disease is responsible for 48,000 deaths a year
in the USA - the ninth leading cause of death - and related
healthcare spending tops US$50 billion a year.
Dialysis treatment alone costs US$72,000 per person per year,
according to the US Renal Data System. Diabetes accounts for 44% of
chronic kidney disease cases in the USA.
Proteomics International Managing Director Dr Richard Lipscombe
said PromarkerD was a major weapon in the battle against the
diabetes epidemic. "Regular testing and early diagnosis of diabetic
kidney disease with PromarkerD can help millions of people avoid
costly and invasive dialysis treatment or a kidney transplant," he
said.
"We are very excited to launch this product nationally across the
USA," said Jim Canfield, President and CEO of PHDx. "This
revolutionary technology will complement PHDx's existing portfolio
to create the leading diabetes test offering in the country. It
will save lives and improve the quality of life for diabetes
sufferers, all while reducing the cost to the healthcare
system."
Under the licence agreement PHDx will develop and commercialise the
PromarkerD mass spectrometry "Laboratory Developed Test" (LDT) in
its specialist certified laboratories. The LDT permits fast
adoption of a new test in advanced markets.
PromarkerD is a simple blood test that uses a unique protein
'fingerprint' to detect signs of disease. PromarkerD is the first
test able to predict the onset of diabetic kidney disease, warning
of a decline in kidney function up to four years in advance. The
test can also diagnose diabetic kidney disease better than the
current gold standard tests.
PromarkerD has the potential to spare millions of people from
future dialysis costs, and save the US healthcare system hundreds
of billions of dollars.
For every million people living with diabetes, 10% - or 100,000
people - are expected to suffer a rapid decline in kidney function
within the next four years. The PromarkerD test is able to predict
this decline in kidney function in 86% of cases. This means that if
every one of the 30 million Americans with diabetes took the test
it would potentially identify 2.6 million of the 3 million people
on the path to kidney disease.
Those identified would require systematic retesting to verify
effectiveness of treatments. Another 84 million American adults -
more than 1 out of 3 - have prediabetes, a precursor to diabetes,
and may also benefit from taking the PromarkerD test.
Dr Lipscombe said the breakthrough deal for PromarkerD in the USA
is important because it paves the way for other licensing
contracts. "It is great to see PromarkerD launching in the world's
largest healthcare market as we further negotiations to
commercialise the test in other countries including Mexico, Japan,
Australia, China and Europe."
About PromarkerD (www.PromarkerD.com)
PromarkerD is a predictive diagnostic test for diabetic kidney
disease. In clinical studies presented in 2017 at the American
Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017]
and published in the prestigious journal Diabetes Care [ASX: 6
September 2017], PromarkerD correctly predicted 86% of otherwise
healthy diabetics who went on to develop chronic kidney disease
within four years.
PromarkerD has been rated the world's leading diagnostic test for
diabetic kidney disease by the global research house Frost &
Sullivan in its report titled Biomarkers Enabling Diabetes and
Obesity Management [ASX: 27 March 2017]. PromarkerD has received
patent protection in several major jurisdictions including the USA,
China, Europe and Japan, with others pending. Further information
is available through the PromarkerD web portal.
About PHDx, Inc (www.phdxinc.com)
PrismHealthDx, Inc. (PHDx) is a precision medicine diagnostic
laboratory and services company specialising in comprehensive
biomarker testing to detect the onset of disease and serious
medical conditions at their earliest and most treatable stage. PHDx
provides a 'one-stop-shop' opportunity to integrate best-in-class
laboratory and clinical medicine into practices, driving better
clinical outcomes and helping to make an immediate difference in
the lives of their patients.
PHDx's management team has extensive experience in developing and
commercialising novel assays and they are committed to advancing
new diagnostic and disease management capabilities. PHDx works in
partnership with academic leaders, industry leaders, and clinical
providers.
About Proteomics International Laboratories (PILL)
Proteomics International (Perth, Western Australia) is a wholly
owned subsidiary and trading name of PILL (ASX: PIQ), a medical
technology company at the forefront of predictive diagnostics and
bio-analytical services. The company specialises in the area of
proteomics - the industrial scale study of the structure and
function of proteins. It received the world's first ISO 17025
laboratory accreditation for proteomics services, and operates from
state-of-the art facilities located on Perth's QEII Medical Campus.
The Company's business model uses its proprietary technology
platform across three integrated areas of diagnostics, drug
discovery and analytical services.
www.proteomicsinternational.com.
Medical Contact:
Chuck Morrison
Head of Business Development
Proteomics International
T: +1 617 331 2975
E: c.morrison@proteomicsinternational.com
Jim Canfield
President & CEO
PrismHealthDx, Inc. (PHDx )
T: +1 770 335 0334
Media Contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
T: +1 650 798 5238
T: +61 2 8218 2144
Source: Proteomics International Laboratories Ltd (PILL)
Copyright 2018 ACN Newswire . All rights reserved.
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024